Importance of Driver Gene Mutation Assessment and Targeted Therapy for Patients with Early‑stage Non‑small Cell Lung Cancer and Non‑R0 Resection

Overview

Journal Oncol Lett

Specialty Oncology

Date 2024 Nov 8

PMID 39512503

Authors

Pei-Yi Shen

Cheng-Yen Chuang

Chih-Hung Lin

Yu-Wei Hsu

Yen-Hsiang Huang

Kuo-Hsuan Hsu

Jeng-Sen Tseng

Gee-Chen Chang

Tsung-Ying Yang

Affiliations

Soon will be listed here.

Abstract

Patients with non-small cell lung cancer (NSCLC) and incomplete resection have poor clinical outcomes. The present study aimed to identify risk factors for disease progression and mortality. A total of 65 patients with early-stage NSCLC that underwent operation but had a non-R0 resection between August 2011 and December 2020 were included in the present study, and the clinicopathological features and driver gene mutation status were analyzed. The median follow-up time was 36.2 months; 39 patients (60.0%) experienced disease progression and 3 patients (4.6%) died. In total, 22 patients (33.8%) harbored mutations in driver genes. Multivariate analysis demonstrated that the presence of driver gene mutations was associated with an increased risk of disease progression [adjusted odds ratio, 24.08; 95% confidence interval (CI), 2.77-209.01; P=0.004]. Tumors classed as Eastern Cooperative Oncology Group performance status 2 [adjusted hazard ratio (HR), 3.49; 95% CI, 1.10-11.03; P=0.033], stage II-IIIB tumors (adjusted HR, 2.55; 95% CI, 1.06-6.17; P=0.037) and the presence of a driver gene mutation (adjusted HR, 3.28; 95% CI, 1.55-6.94; P=0.002) were associated with a significantly reduced progression-free survival (PFS). Driver gene-targeted therapy was associated with an increased post-progression survival for patients that were reported to have disease progression (adjusted HR, 0.38; 95% CI, 0.16-0.91; P=0.030). There was no significant impact of driver gene mutation status on the overall survival (OS) of patients. Although the presence of a driver gene mutation was associated with an increased risk of disease progression and a reduced PFS, it was demonstrated that patients with disease progression may benefit from driver gene-targeted therapy, as patients with driver gene-targeted therapy had a similar OS compared with that of patients with a driver gene-negative or unknown status. Therefore, early comprehensive analysis of driver gene mutation status may be recommended for early-stage NSCLC cancer patients experiencing non-R0 resection.

References

Shin S, Lee H, Jeong B, Choi Y, Shin M, Kim S . Anaplastic lymphoma kinase rearrangement in surgically resected stage IA lung adenocarcinoma. J Thorac Dis. 2018; 10(6):3460-3467. PMC: 6051845. DOI: 10.21037/jtd.2018.05.131. View

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

Osarogiagbon R, Lin C, Smeltzer M, Jemal A . Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non-Small Cell Lung Cancer in the U.S. National Cancer Data Base. J Thorac Oncol. 2016; 11(1):e5-16. PMC: 4714753. DOI: 10.1016/j.jtho.2015.08.002. View

Carnio S, Novello S, Papotti M, Loiacono M, Scagliotti G . Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures. Transl Lung Cancer Res. 2015; 2(5):372-81. PMC: 4367732. DOI: 10.3978/j.issn.2218-6751.2013.10.05. View

de Koning H, van der Aalst C, de Jong P, Scholten E, Nackaerts K, Heuvelmans M . Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020; 382(6):503-513. DOI: 10.1056/NEJMoa1911793. View

Su K, Kao J, Ho B, Chen H, Chang G, Ho C . Implementation and Quality Control of Lung Cancer EGFR Genetic Testing by MALDI-TOF Mass Spectrometry in Taiwan Clinical Practice. Sci Rep. 2016; 6:30944. PMC: 4969598. DOI: 10.1038/srep30944. View

Kato S, Goodman A, Walavalkar V, Barkauskas D, Sharabi A, Kurzrock R . Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res. 2017; 23(15):4242-4250. PMC: 5647162. DOI: 10.1158/1078-0432.CCR-16-3133. View

Chang Y, Huang J, Lin C, Wang B . Survival and Treatment of Lung Cancer in Taiwan between 2010 and 2016. J Clin Med. 2021; 10(20). PMC: 8540538. DOI: 10.3390/jcm10204675. View

Hsu K, Ho C, Hsia T, Tseng J, Su K, Wu M . Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan. PLoS One. 2015; 10(3):e0120852. PMC: 4366385. DOI: 10.1371/journal.pone.0120852. View

10.

Pignon J, Tribodet H, Scagliotti G, Douillard J, Shepherd F, Stephens R . Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26(21):3552-9. DOI: 10.1200/JCO.2007.13.9030. View

11.

Edwards J, Chansky K, Van Schil P, Nicholson A, Boubia S, Brambilla E . The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non-Small Cell Lung Cancer. J Thorac Oncol. 2019; 15(3):344-359. DOI: 10.1016/j.jtho.2019.10.019. View

12.

Ni Y, Lei J, Huang W, Wang J, Guo H, Lv F . Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis. Front Oncol. 2023; 13:1092663. PMC: 10172597. DOI: 10.3389/fonc.2023.1092663. View

13.

Park H, Choi Y, Yun J, Song S, Na K, Yoon J . Genetic Alterations and Risk Factors for Recurrence in Patients with Non-Small Cell Lung Cancer Who Underwent Complete Surgical Resection. Cancers (Basel). 2023; 15(23). PMC: 10705717. DOI: 10.3390/cancers15235679. View

14.

Church T, Black W, Aberle D, Berg C, Clingan K, Duan F . Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 2013; 368(21):1980-91. PMC: 3762603. DOI: 10.1056/NEJMoa1209120. View

15.

Ou W, Liao P, Hsu Y, Huang Y, Hsu K, Tseng J . Outcome of Thromboembolic Events and Its Influence on Survival Time of Advanced NSCLC Patients Treated with Antiangiogenic Therapy. Cancer Manag Res. 2023; 15:1251-1262. PMC: 10637185. DOI: 10.2147/CMAR.S430868. View

16.

Mescam-Mancini L, Lantuejoul S, Moro-Sibilot D, Rouquette I, Souquet P, Audigier-Valette C . On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer. 2014; 83(2):168-73. DOI: 10.1016/j.lungcan.2013.11.019. View

17.

Detterbeck F . The eighth edition TNM stage classification for lung cancer: What does it mean on main street?. J Thorac Cardiovasc Surg. 2017; 155(1):356-359. DOI: 10.1016/j.jtcvs.2017.08.138. View

18.

Udelsman B, Blasberg J . Advances in Surgical Techniques for Lung Cancer. Hematol Oncol Clin North Am. 2023; 37(3):489-497. DOI: 10.1016/j.hoc.2023.02.006. View

19.

Tseng J, Yang T, Tsai C, Chen K, Hsu K, Tsai M . Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma. J Thorac Oncol. 2014; 10(4):603-10. DOI: 10.1097/JTO.0000000000000443. View

20.

Fujibayashi Y, Tane S, Kitazume M, Kuroda S, Kimura K, Kitamura Y . Resected stage I anaplastic lymphoma kinase-positive lung adenocarcinoma has a negative impact on recurrence-free survival. Thorac Cancer. 2022; 13(8):1109-1116. PMC: 9013641. DOI: 10.1111/1759-7714.14365. View